Nkarta (NKTX) vs Outlook Therapeutics (OTLK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Nkarta (NKTX) has outperformed Outlook Therapeutics (OTLK) over the past year, losing 4.7% versus a loss of 51.3%. Over five years, NKTX leads with a -87.7% price change compared with -98.6% for OTLK. Nkarta is the larger company by market cap ($161.2 million vs $145.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NKTX | OTLK |
|---|---|---|
| Share price | $2.25 | $0.5989 |
| Market cap | $161.16M | $145.80M |
| 1-day change | +1.35% | +6.19% |
| YTD return | +21.62% | -62.09% |
| 1-year return | -4.66% | -51.31% |
| 5-year return | -87.73% | -98.58% |
| EPS (TTM) | $-1.58 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.72 | $2.54 |
| 52-week low | $1.70 | $0.161 |
| Distance from 52-week high | -39.52% | -76.40% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +381.33% | +739.87% |
| Average volume | 606.90K | 13.28M |
| Shares outstanding | 71.62M | 243.45M |
| Employees | 106 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NKTX has outperformed OTLK by 46.6 percentage points over the past year.
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
NKTX vs OTLK FAQ
Which is bigger, Nkarta or Outlook Therapeutics?
Nkarta (NKTX) is larger, with a market capitalization of $161.16M compared with $145.80M for Outlook Therapeutics (OTLK).
Which stock has performed better over the past year, NKTX or OTLK?
NKTX returned -4.66% over the past 12 months, compared with -51.31% for OTLK (price return, excluding dividends). Past performance does not predict future results.
Are Nkarta and Outlook Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Nkarta and Biotechnology: Biological Products (No Diagnostic Substances) for Outlook Therapeutics.